Tofacitinib for ulcerative colitis in Brazil: a multicenter observational study on effectiveness and safety.
Parra RS, de Sá Brito Fróes R, Magro DO, da Costa Ferreira S, de Mello MK, de Azevedo MFC, Damião AOMC, de Sousa Carlos A, Barros LL, de Miranda MLQ, Vieira A, Sales MPM, Zabot GP, Cassol OS, Tiburcio Alves AJ Jr, Lubini M, Machado MB, Flores C, Teixeira FV, Coy CSR, Zaltman C, Chebli LA, Sassaki LY, Féres O, Chebli JMF.
Parra RS, et al.
BMC Gastroenterol. 2025 Mar 18;25(1):184. doi: 10.1186/s12876-025-03656-x.
BMC Gastroenterol. 2025.
PMID: 40102788
Free PMC article.
Clinical remission and response, endoscopic response and remission, biochemical response and remission, steroid-free clinical remission, primary and secondary loss of response, drug discontinuation, the need for dose optimization, the need for colectomy, and adverse events were e …
Clinical remission and response, endoscopic response and remission, biochemical response and remission, steroid-free clinical remission, pri …